Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HPGD | P15428 | 4/20 | 0.70 |
| ▸ | CA1 | P00915 | 2/20 | 0.62 |
| ▸ | CA2 | P00918 | 2/20 | 0.62 |
| ▸ | CA4 | P22748 | 2/20 | 0.62 |
| ▸ | CA9 | Q16790 | 2/20 | 0.62 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.61 |
| ▸ | USP2 | O75604 | 1/20 | 0.61 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.57 |
| ▸ | HTT | P42858 | 1/20 | 0.57 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.56 |
| ▸ | PTGS2 | P35354 | 2/20 | 0.56 |
| ▸ | LMNA | P02545 | 1/20 | 0.55 |
| ▸ | ATM | Q13315 | 1/20 | 0.54 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.54 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.54 |
| ▸ | MEN1 | O00255 | 3/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.47 |
| ▸ | MAPT | P10636 | 2/20 | 0.47 |
| ▸ | NPC1 | O15118 | 1/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4141641 | 1.00 | HPGD (0.70) | HPGDCA1CA2CA4CA9 | |
| SCHEMBL4141640 | 1.00 | HPGD (0.70) | HPGDCA1CA2CA4CA9 | |
| SCHEMBL4130916 | 0.82 | HPGD (1.00) | HPGDCA1CA2CA4CA9 | |
| SCHEMBL14421623 | 0.82 | HPGD (0.71) | HPGDCA1CA2CA4CA9 | |
| SCHEMBL4130917 | 0.82 | HPGD (1.00) | HPGDCA1CA2CA4CA9 | |
| SCHEMBL4128453 | 0.82 | HPGD (0.71) | HPGDCA1CA2CA4CA9 | |
| SCHEMBL4128452 | 0.82 | HPGD (0.71) | HPGDCA1CA2CA4CA9 | |
| SCHEMBL13931548 | 0.82 | ALDH1A1 (0.65) | HPGDCA1CA2CA4CA9 | |
| SCHEMBL13931545 | 0.78 | HPGD (0.65) | HPGDCA1CA2CA4CA9 | |
| SCHEMBL4246544 | 0.77 | ALDH1A1 (0.69) | HPGDCA1CA2CA4CA9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 26 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230105595-A1 | PROCESS OF PREPARING 2-(PHENYLIMINO)-3-ALKYL-1,3-THIAZOLIDIN-4-ONES | BAYER AKTIENGESELLSCHAFT (DE) | 2023-04-06 | — | — | US | claimed |
| EP-4107149-A1 | PROCESS OF PREPARING 2-(PHENYLIMINO)-3-ALKYL-1,3-THIAZOLIDIN-4-ONES | Bayer Aktiengesellschaft (DE) | 2022-12-28 | — | — | EP | claimed |
| CN-115103838-A | Process for the preparation of 2- (phenylimino) -3-alkyl-1, 3-thiazolidin-4-ones | 拜耳公司 | 2022-09-23 | — | — | CN | claimed |
| EP-4013744-A1 | PROCESS OF PREPARING 2-(PHENYLIMINO)-3-ALKYL-1,3-THIAZOLIDIN-4-ONES | Bayer Aktiengesellschaft (DE) | 2022-06-22 | — | — | EP | claimed |
| CN-114269726-A | Process for preparing 2- (phenylimino) -3-alkyl-1, 3-thiazolidin-4-ones | 拜耳公司 | 2022-04-01 | — | — | CN | claimed |
| WO-2021028518-A1 | PROCESS OF PREPARING 2-(PHENYLIMINO)-3-ALKYL-1,3-THIAZOLIDIN-4-ONES | BAYER AKTIENGESELLSCHAFT (DE) | 2021-02-18 | — | — | WO | claimed |
| US-20240199560-A1 | PROCESS FOR PREPARING (2Z)-2-(PHENYLIMINO)-1,3-THIAZOLIDINE-4-ONE-SULFOXIDE DERIVATIVES IN AN ENANTIOMERICALLY ENRICHED FORM | BAYER AKTIENGESELLSCHAFT (DE) | 2024-06-20 | — | — | US | disclosed |
| US-20240199560-A1 | PROCESS FOR PREPARING (2Z)-2-(PHENYLIMINO)-1,3-THIAZOLIDINE-4-ONE-SULFOXIDE DERIVATIVES IN AN ENANTIOMERICALLY ENRICHED FORM | BAYER AKTIENGESELLSCHAFT (DE) | 2024-06-20 | — | — | US | disclosed |
| CN-116981659-A | Process for preparing enantiomerically enriched (2Z) -2- (phenylimino) -1, 3-thiazolidin-4-one sulfoxide derivatives | 拜耳公司 | 2023-10-31 | — | — | CN | disclosed |
| CN-116981659-A | Process for preparing enantiomerically enriched (2Z) -2- (phenylimino) -1, 3-thiazolidin-4-one sulfoxide derivatives | 拜耳公司 | 2023-10-31 | — | — | CN | disclosed |
| US-20230105595-A1 | PROCESS OF PREPARING 2-(PHENYLIMINO)-3-ALKYL-1,3-THIAZOLIDIN-4-ONES | BAYER AKTIENGESELLSCHAFT (DE) | 2023-04-06 | — | — | US | disclosed |
| EP-4107149-A1 | PROCESS OF PREPARING 2-(PHENYLIMINO)-3-ALKYL-1,3-THIAZOLIDIN-4-ONES | Bayer Aktiengesellschaft (DE) | 2022-12-28 | — | — | EP | disclosed |
| CN-115103838-A | Process for the preparation of 2- (phenylimino) -3-alkyl-1, 3-thiazolidin-4-ones | 拜耳公司 | 2022-09-23 | — | — | CN | disclosed |
| US-20110190299-A1 | THIAZOLIDINONE DERIVATIVE | SBI BIOTECH CO., LTD. (JP) | 2011-08-04 | — | — | US | disclosed |
| US-20090203692-A1 | NOVEL CHEMICAL COMPOUNDS | SMITHKLINE BEECHAM CORPORATION | 2009-08-13 | — | — | US | disclosed |
| US-20090048252-A1 | THIAZOLONES FOR USE AS PI3 KINASE INHIBITORS | SMITHKLINE BEECHAM CORPORATION | 2009-02-19 | — | — | US | disclosed |
| US-20090048252-A1 | THIAZOLONES FOR USE AS PI3 KINASE INHIBITORS | SMITHKLINE BEECHAM CORPORATION | 2009-02-19 | — | — | US | disclosed |
| US-20070249599-A1 | Novel Chemical Compounds | DUFFY KEVIN J | 2007-10-25 | — | — | US | disclosed |
| US-20070249599-A1 | Novel Chemical Compounds | DUFFY KEVIN J | 2007-10-25 | — | — | US | disclosed |
| WO-2007103755-A2 | THIAZOLONES FOR USE AS PI3 KINASE INHIBITORS | SMITHKLINE BEECHAM CORPORATION (US) | 2007-09-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230105595-A1 | PROCESS OF PREPARING 2-(PHENYLIMINO)-3-ALKYL-1,3-THIAZOLIDIN-4-ONES | CYP1A1, CYP2S1, CYP1A2 | HPGD 1447/4885CA1 4072/4885CA2 2494/4885 |
| US-20070249599-A1 | Novel Chemical Compounds | HIPK3, HIPK1, HIPK4 | HPGD 3707/4885CA1 4878/4885CA2 4695/4885 |
| US-20110190299-A1 | THIAZOLIDINONE DERIVATIVE | CDC7, CDK17, CDCA2 | HPGD 3970/4885CA1 4525/4885CA2 3377/4885 |
| US-20090048252-A1 | THIAZOLONES FOR USE AS PI3 KINASE INHIBITORS | PIK3CA, BTK, PI4KA | HPGD 3782/4885CA1 4309/4885CA2 1982/4885 |
| US-20240199560-A1 | PROCESS FOR PREPARING (2Z)-2-(PHENYLIMINO)-1,3-THIAZOLIDINE-4-ONE-SULFOXIDE DERIVATIVES IN AN ENANTIOMERICALLY ENRICHED FORM | CYP2S1, SULT1E1, SULT1A1 | HPGD 1035/4885CA1 3448/4885CA2 4051/4885 |
| US-20090203692-A1 | NOVEL CHEMICAL COMPOUNDS | HIPK3, HIPK1, HIPK4 | HPGD 3497/4885CA1 4864/4885CA2 4510/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.